Interactively stimulating collaborations, advancing biomarker development and ensuring diagnostics continue to play a critical role in therapeutic development

Develop, Validate & Commercialize Clinically Effective Targeted Therapeutics

The diagnostic field is booming with global interest as companies race to be the first to develop diagnostics and vaccines for the novel coronavirus. More than ever before we are seeing diagnostic, pharmaceutical and academic expertise coming together to deliver in record-breaking speed. As attention starts to shift back to existing pipeline candidates, what lessons can we learn to deliver personalized therapies in a more time effective manner?

Uniting biomarker, translational, clinical, diagnostic and commercial thought leaders, the
Digital Clinical Biomarkers & World CDx meeting will address key questions raised following the rapid COVID-19 response and delivers exciting case studies from pioneering teams in personalized therapeutics. Helping you expedite end-to-end drug development; this is not a conversation to miss.

With three days dedicated to help you overcome your most pressing challenges, ensure you are here for conversations with pharma on the COVID response, the rise of T-cell based therapeutics in personalized medicine and exciting case studies spanning early studies to delivering commercial strategies

Key Speakers

Tooba Cheema

Director, Translational Medicine & Biomarkers

Oncorus

Jennifer Hamilton

Executive Director & Head, Precision Medicine

Regeneron

Sid Mathur

Regulatory Affairs Director, Companion Diagnostics

Merck & Co.

Julie Ramage

Director, Precision Medicine Quality Initiatives & Partnerships

AstraZeneca

Lourdes Barrera

Senior Director, Precision Medicine, Global Precision Medicine Strategy, Oncology Business Unit

Novartis

Jeffrey Emch

Vice President, Global Companion Diagnostics Strategy, Oncology

GSK

Beth Trehu

Chief Medical Officer

Jounce Therapeutics

Roman Yelensky

Chief Technology Officer

Gritstone Oncology